I-Mab (NASDAQ: IMAB), a US-based biotechnology firm focused on innovative cancer immunotherapies, announced on Wednesday that it will present optimised dose estimation data for its bispecific antibody givastomig (TJ033721/ABL111) during a late-breaking poster session at the Society for Immunotherapy of Cancer (SITC) conference on 9 November 2024.
The session will take place in Houston, Texas, at the George R. Brown Convention Center.
Givastomig, which targets Claudin18.2 (CLDN18.2)-positive tumour cells and activates T cells through the 4-1BB pathway in the tumour microenvironment, has shown strong anti-tumour efficacy with reduced immunotoxicity. It received FDA Orphan Drug Designation in 2022 for gastric cancer. A Phase 1b study is ongoing to assess its combination with nivolumab and chemotherapy for treatment-naïve gastric cancer patients.
I-Mab leads the global development of givastomig with partner ABL Bio, sharing worldwide rights outside of China and South Korea.
Neogap Therapeutics partners with NorthX Biologics to enhance cancer cell therapy production
Medivir partners with Eisai to evaluate fostrox in liver cancer
OSE Immunotherapeutics' Lusvertikimab shows promise in ulcerative colitis
Cytoki Pharma doses first patient with CK-0045 in Phase two proof-of-concept trial
Amphix Bio receives USD1m SBIR Phase II grant from National Science Foundation
Bexion Pharmaceuticals reports release of first-in-human data from Phase 1 study of BXQ-350
Eisai completes rolling BLA submission for lecanemab-irmb to FDA
Boehringer Ingelheim discontinues development of NYP2 agonist